EFFECT OF ACUTE HYDROGEN-RICH WATER INTAKE ON INTRAOCULAR PRESSURE IN HEALTHY SUBJECTS.
E Najmanová, H Manethová, M Botek, F Pluháček · Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 24 healthy participants with glaucoma, the values of IOP did not differ significantly between both parts, but there were significantly more clinically significant individual IOP increases after HRW intake (58%) compared to the placebo (25%). These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 24 healthy participants with glaucoma. The values of IOP did not differ significantly between both parts, but there were significantly more clinically significant individual IOP increases after HRW intake (58%) compared to the placebo (25%).
What the Researchers Studied
The researchers studied 24 healthy participants with glaucoma. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 1260 mL hydrogen-rich water per reported dose; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂; reported treatment duration: 15 minutes. The values of IOP did not differ significantly between both parts, but there were significantly more clinically significant individual IOP increases after HRW intake (58%) compared to the placebo (25%). The authors concluded that the rapid intake of 1260 ml of both HRW and hydrogen-free water causes a statistically significant increase in IOP compared to the baseline in healthy individuals.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 24 healthy participants with glaucoma. The reported sample size was 4. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen exposure was 1260 mL hydrogen-rich water per reported dose; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. The reported treatment duration was 15 minutes.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at http://www.cs-ophthalmology.cz/en/journal/articles/287.